hackint0sh/New-Dataset huggingface dataset:
Participants in the active control condition will walk for 30 minutes without further instruction. conditions: Spiritual Well-being conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Contemplating in nature name: Walking in nature measure: Spiritual well-being assessed by Spiritual Attitude and Involvement List Short Form (SAIL-SF) measure: Spiritual well-being assessed by Spiritual Attitude and Involvement List Short Form (SAIL-SF) measure: Spiritual well-being assessed by Spiritual Attitude and Involvement List Short Form (SAIL-SF) measure: Spiritual well-being assessed by Daily Spiritual Experience Scale (DSES) measure: Spiritual well-being assessed by Daily Spiritual Experience Scale (DSES) measure: Spiritual well-being assessed by Daily Spiritual Experience Scale (DSES) measure: Client satisfaction of intervention condition assessed by Client Satisfaction Questionnaire (CSQ-8) measure: Client satisfaction of active control condition assessed by Client Satisfaction Questionnaire (CSQ-8) measure: Client satisfaction of passive control condition assessed by Client Satisfaction Questionnaire (CSQ-8) measure: Nature connectedness assessed by Connectedness to Nature Scale (CNS) measure: Nature connectedness assessed by Connectedness to Nature Scale (CNS) measure: Nature connectedness assessed by Connectedness to Nature Scale (CNS) measure: Nature connectedness assessed by the single item Inclusion of Nature with Self scale (INS) measure: Nature connectedness assessed by the single item Inclusion of Nature with Self scale (INS) measure: Nature connectedness assessed by the single item Inclusion of Nature with Self scale (INS) measure: Well-being assessed by Mental Health Continuum-Short Form (MHC-SF) measure: Well-being assessed by Mental Health Continuum-Short Form (MHC-SF) measure: Well-being assessed by Mental Health Continuum-Short Form (MHC-SF) measure: Psychological well-being assessed by Brief INSPIRE-O measure: Psychological well-being assessed by Brief INSPIRE-O measure: Psychological well-being assessed by Brief INSPIRE-O measure: Stress assessed by Perceived Stress Scale (PSS) measure: Stress assessed by Perceived Stress Scale (PSS) measure: Stress assessed by Perceived Stress Scale (PSS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Twente city: Enschede state: Overijssel zip: 7522NB country: Netherlands name: TALITHA RUARUS-BLANKERT role: CONTACT phone: +31534891289 email: pgt@utwente.nl name: Ernst Bohlmeijer, Prof. Dr. role: PRINCIPAL_INVESTIGATOR lat: 52.21833 lon: 6.89583 hasResults: False
nctId: NCT06365723 id: SPH-2023-32410 briefTitle: Effects of Walking in Greenspace and the Built Environment in Adults With Prediabetes: A Randomized Crossover Trial overallStatus: NOT_YET_RECRUITING date: 2025-01-15 date: 2030-06-15 date: 2032-06-15 date: 2024-04-15 date: 2024-04-15 name: University of Minnesota class: OTHER briefSummary: Approximately 92 million U.S. adults (\~38% of population) have prediabetes (PreD). Because people with PreD are at high risk CMD, they are a target population for diabetes prevention programs. The focus is people with PreD because of their high risk for developing CMD and large numbers, providing an opportunity to investigate behavioral and environmental approaches as preventive measures in a well-defined population. Urbanization affords challenges and opportunities to public health that include exposure to obesogenic environments, air pollution, and psychosocial stressors. In healthy adults suggest exposure to nature has health benefits relative to exposure to built environments. Hypothesized mechanisms for health benefits of Greenspace exposure include increased physical activity (PA), attention restoration, stress reduction, and reduced exposure to pollution. Many of the health benefits are associated with reduced psychological and physiological stress leading to better autonomic functioning as assessed by heart rate variability (HRV) and other biomarkers. Multiple studies suggest that PA and exposure to natural environments may act together to improve health. Yet, aside from our preliminary studies, we are not aware of any studies that examined how physical activity may interact with exposure to urban Greenspace ('Green') compared with built urban environments ('Gray'), to reduce stress and improve health. The purpose of this proposed study is to conduct a randomized crossover trial comparing differences in the psychosocial and physiological effects of walking in urban Green and Gray spaces in adults with PreD. conditions: PreDiabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study is a randomized crossover trial with a 4-week washout period. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 216 type: ESTIMATED name: Green Walk name: Gray Walk measure: Measure of Anxiety measure: Perceived stress assessment measure: Mood assessment measure: Heart Rate variability measure: Salivary cortisol levels measure: Ambient Particulate Matter measure: Black Carbon levels measure: CMD risk measure: State and Trait anxiety sex: ALL minimumAge: 25 Years maximumAge: 64 Years stdAges: ADULT hasResults: False
nctId: NCT06365710 id: HUS/206/2022 briefTitle: Physiotherapy vs Telerehabilitation After Volar Plating of Distal Radius Fracture overallStatus: RECRUITING date: 2022-11-24 date: 2025-01-31 date: 2026-01-31 date: 2024-04-15 date: 2024-04-15 name: Töölö Hospital class: OTHER briefSummary: Trial purpose is to research the outcome comparing traditional physiotherapy vs telerehabilitation after volar plating of distal radius fracture.
Baseline data is collected preoperatively and patients are followed at 1, 3 and 12 months after enrollment. The primary end-point is 3 months and the primary outcome is the Patient-Rated Wrist Evaluation (PRWE). conditions: Orthopedic Procedures, Physical Therapy Modalities, Postoperative Care, Rehabilitation, Wrist Fractures studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 84 type: ESTIMATED name: Telerehabilitation name: Traditional physiotherapy measure: Patient-Rated Wrist Evaluation (PRWE) measure: Grip strength measure: Quick Disabilities of the arm, shoulder, and hand measure: Pain (Visual Analogue Scale) measure: Wrist range of motion (ROM) measure: Adverse events measure: Global improvement measure: Patient-rated Quality of Life (EQ-5D) measure: Cost-utility analysis sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Division of Musculosceletal and Plastic Surgery, Hand Surgery Unit, Helsinki University Hospital status: RECRUITING city: Helsinki state: Uusimaa zip: 00029 country: Finland name: Samuli Aspinen, M.D., Ph.D. role: CONTACT phone: +358406360546 email: samuli.aspinen@hus.fi lat: 60.16952 lon: 24.93545 hasResults: False
nctId: NCT06365697 id: ZHTQ202301 briefTitle: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-11 date: 2025-10 date: 2024-04-15 date: 2024-04-15 name: Zhuhai Tonbridge Medical Tech. Co., Ltd. class: INDUSTRY briefSummary: The purpose of this trial is to evaluate effectiveness and safety of the Ton-bridge carotid stent for the treatment of carotid artery stenosis. conditions: Carotid Artery Stenosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 188 type: ESTIMATED name: Ton-bridge carotid stent name: WALLSTENT carotid stent measure: Incidence of non-MAE(major adverse events) within 30 days post-procedure measure: Technical success measure: Procedural success measure: Target lesion revascularization (TLR) measure: Ipsilateral stroke between 31 days and 1 year post-procedure measure: In-stent restenosis measure: mRS score measure: Device deficiency measure: Incidence of MAE measure: Incidence of Adverse events (AE) measure: Incidence of Serious adverse events (SAE) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The People's Hospital of Liaoning Province city: Shenyang state: Liaoning country: China name: Peizhuo Zang role: PRINCIPAL_INVESTIGATOR lat: 41.79222 lon: 123.43278 facility: Linyi People's Hospital city: Linyi state: Shandong country: China name: Hongxing Han role: PRINCIPAL_INVESTIGATOR lat: 35.06306 lon: 118.34278 facility: Qingdao Central Hospital city: Qingdao state: Shandong country: China name: Haicheng Yuan role: PRINCIPAL_INVESTIGATOR lat: 36.06488 lon: 120.38042 facility: The Affiliated Hospital of Qingdao University city: Qingdao state: Shandong country: China name: Yong Zhang role: PRINCIPAL_INVESTIGATOR lat: 36.06488 lon: 120.38042 facility: Central Hospital Affiliated to Shangdong First Medical University city: Jinan state: Shangdong country: China name: Liqun Jiao role: PRINCIPAL_INVESTIGATOR lat: 36.66833 lon: 116.99722 facility: Lishui Central Hospital city: Lishui state: Zhejiang country: China name: Xueli Cai role: PRINCIPAL_INVESTIGATOR lat: 28.46042 lon: 119.91029 facility: Xuanwu Hospital, Capital Medical University city: Beijing country: China name: Bin Yang role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06365684 id: 133548 id: 2023-507823-52 type: EUDRACT_NUMBER briefTitle: Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 acronym: LIBRAL overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2025-05-01 date: 2025-05-01 date: 2024-04-15 date: 2024-04-24 name: Leiden University Medical Center class: OTHER name: AstraZeneca briefSummary: Rationale: Several studies have shown that higher urinary potassium excretion (as proxy for potassium intake) is associated with better kidney outcomes, lower blood pressure and improved survival. These associations are also observed in patients with (advanced) CKD. However, application in daily practice in patients with CKD, is impaired by the risk of hyperkalemia, due to metabolic acidosis and impaired renal potassium excretion in these patients. As a consequence, patients with CKD are advised to restrict their intake of fruit and vegetables, as these healthy food components are important sources of dietary potassium. This is particularly undesirable for patients with CKD in view of the very high risk of cardiovascular disease.
Objective: To demonstrate that a potassium-rich diet, including the use of SZC as potential rescue treatment (in case of hyperkalemia), does not result in an unacceptable rise in plasma potassium (i.e. max rise of 0.5 mmol/L and no hyperkalemia). Study Design: Investigator initiated, single center, cross-over randomized clinical trial with non-inferiority design (14 weeks, 2 groups: regular diets vs. diet with potassium rich fruits and vegetables with sodium zirconium cyclosilicate if necessary) Study population: Outpatients ( age ≥ 18 years ) with chronic kidney disease stage IIIb/IV and use of inhibitor of the renin-angiotensin system (RASi).
Intervention: Addition of fruit- and vegetables that contain 40 mmol of potassium on top of regular diet. Addition of SZC after 1 week in case hyperkaliemia develops (serum potassium \> 5,5 mmol/L). Weekly measurement of plasma potassium and dose adjustment of SZC if needed conditions: Hyperkalemia conditions: Diet Modification conditions: Chronic Kidney Disease conditions: Sodium Zirconium Cyclosilicate studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Single center, cross-over randomized clinical trial with non-inferiority design primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: Sodium zirconium cyclosilicate measure: The difference of serum potassium at baseline and after six weeks of treatment with potassium enriched diet (non-inferiority design) compared to the control group. With an intention to treat analysis. measure: Ambulatory blood pressure (average systolic and diastolic blood pressure over 24 hours) measure: 24 hours albuminuria measure: urinary potassium (mmol/l) measure: Plasma bicarbonate measure: Quality of life, using SF36 questionnaire measure: Effect on stool (assessed with Bristol Stool Chart) measure: Difference in serum potassium one week after start of study (SCZ free period) measure: Per protocol analysis of difference in serum potassium after six week (end of study) measure: Incidence of severe hyperkalemia (serum potassium above 6.5 mmol/l or above 6.0 with ECG features of hyperkalemia) measure: Incidence of hyperkalemia (serum potassium above 5.5 mmol/l) measure: Necessity for treatment of hyperkalemia measure: urinary sodium (mmol/l) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06365671 id: ASCT-CART briefTitle: CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2027-04 date: 2024-04-15 date: 2024-04-15 name: Ruijin Hospital class: OTHER briefSummary: Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors conditions: B-NHL, Extranodal, TP53 Alterations, Bulky Mass studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel) measure: Best Complete Response (CR) Rate in 3 months measure: Objective remission rate (ORR) in 3months measure: Duration of Response (DOR) measure: Progression-Free Survival (PFS) measure: Overall Survival (OS) measure: Adverse Events rate as assessed by CTCAE version 5.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06365658 id: 2024/PTPiP/1 briefTitle: Cognitive Functioning in Adults With Somatic Diseases and General Population From a Biopsychosocial Perspective overallStatus: RECRUITING date: 2023-07-03 date: 2025-03 date: 2025-12 date: 2024-04-15 date: 2024-04-22 name: Bartosz M. Radtke class: OTHER_GOV briefSummary: The goal of this observational study is to investigate cognitive functioning profiles in adults with neurologically recognized aphasic syndromes and general population.
3. seniors (over 60 y.o.) conditions: Aphasia conditions: Development, Human conditions: Neuropathology studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 600 type: ESTIMATED name: Psychological assessment measure: Memory and learning measure: Language measure: Socio-demographic data measure: General mental state measure: Health related data measure: Education data sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Laboratory of Psychological and Educational Tests status: RECRUITING city: Gdansk state: Pomerania zip: 80-239 country: Poland name: Rafał Nowicki, M.A. role: CONTACT phone: +48509805591 email: nowicki@pracowniatestow.pl name: Urszula Sajewicz-Radtke, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Bartosz M Radtke, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Ariadna Łada-Maśko, Ph.D. role: PRINCIPAL_INVESTIGATOR name: Beata Daniluk, Ph.D. role: SUB_INVESTIGATOR name: Piotr Markiewicz, Ph.D. role: SUB_INVESTIGATOR name: Paweł Jurek, Ph.D. role: SUB_INVESTIGATOR name: Michał Olech, Ph.D. role: SUB_INVESTIGATOR name: Artur Sawicki, M.A. role: SUB_INVESTIGATOR name: Rafał Nowicki, M.A. role: SUB_INVESTIGATOR lat: 54.35205 lon: 18.64637 hasResults: False
nctId: NCT06365645 id: 2138752 briefTitle: Feasibility & Acceptability of App-based Cognitive Behavioral Therapy for Postpartum Depression Prevention overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-12 date: 2024-04-15 date: 2024-04-15 name: Women and Infants Hospital of Rhode Island class: OTHER briefSummary: Postpartum depression (PPD) affects up 10-15% of mothers overall, but the rate of PPD can be as high as 25% among mothers with personal or obstetric risk factors. The Mothers \& Babies Program (MB) is a cognitive behavioral therapy (CBT)-based program that has been shown to prevent PPD among high-risk mothers without a prior history of depression. MB has been so consistently effective that the United States Preventive Services Task Force recommends this program be given to high-risk pregnant patients. Originally designed to be given in-person and via groups, MB has been adapted to be given in person one-on-one in clinic or at home and via text message. However, MB has yet to be adapted to a smartphone application (app). Via evidence-based qualitative research and end-user centered design, MB has been adapted to a novel app, M.Bapp. This study aims to examine the feasibility and acceptability of M.Bapp as a study intervention for perinatal patients as well as provide preliminary estimates of effect for the intervention. conditions: Postpartum Depression conditions: Postpartum Anxiety conditions: Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Participants who consent will be unaware of the existence of another version of M.Bapp. Obstetric care providers will be aware of participant's enrollment in this trial but not of the study group and will be encouraged to provide standardized care. The research team and outcomes assessors will be blindd to the randomization group. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: M.Bapp name: App-based parenting education measure: Feasibility measure: Acceptability measure: Edinburgh Postnatal Depression Scale measure: General Anxiety Disorder-7 measure: Perceived Stress-Scale 4 measure: Dyadic Adjustment Scale measure: UCLA Loneliness Scale measure: Frequency of Mothers and Babies Skills Use measure: De novo psychiatric diagnosis measure: Screening positive on study survey sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Women & Infants Hospital of Rhode Island city: Providence state: Rhode Island zip: 02905 country: United States lat: 41.82399 lon: -71.41283 hasResults: False
nctId: NCT06365632 id: OLTOSPAN-02 briefTitle: Clinical Study of the Effectiveness, Tolerability and Safety of the Drug "Anti-spike, Gel, 100 g in Bottles in Package No. 1" Produced by the Republican Unitary Enterprise "Unitekhprom BSU", With a Single Intraperitoneal Use After Surgery in Adult Patients With Acute Phlegmonous Appendicitis acronym: OLTOSPAN-02 overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2024-12 date: 2024-12 date: 2024-04-15 date: 2024-04-15 name: Research Institute for Physical Chemical Problems of the Belarusian State University class: OTHER name: Unitary Enterprise UNITEHPROM BSU name: City Clinical Hospital of Emergency Medical Care of Minsk briefSummary: The purpose of the clinical trials is the evaluation of the effectiveness and safety of a single intraperitoneal use of the drug "Antispike, gel, 100 g in a bottle" produced by Unitary Enterprise Unitehprom BSU, Belarus in patients after surgical control of acute phlegmonous appendicitis to prevent abdominal adhesions. conditions: Abdominal Adhesions studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus name: antegrade appendectomy measure: Number of patients with acute phlegmonous appendicitis cured measure: absence of signs of adhesions measure: increase in the sliding distance of the cecum sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CITY CLINICAL EMERGENCY HOSPITAL of Minsk city: Minsk zip: 220024 country: Belarus name: Olga Svetlitskaya role: CONTACT phone: +375297752697 email: info@bsmp.by name: Yulia Shabalina role: CONTACT phone: +375 (17) 287 00 15 email: info@bsmp.by lat: 53.9 lon: 27.56667 facility: CITY CLINICAL EMERGENCY HOSPITAL of Minsk city: Minsk zip: 220024 country: Belarus name: Olga Svetlitskaya role: CONTACT phone: +375297752697 email: info@bsmp.by name: Yulia Shabalina role: CONTACT phone: +375 (17) 287 00 15 email: info@bsmp.by name: Stanislav Tretiak, Doctor of Medicine role: PRINCIPAL_INVESTIGATOR name: Alexander Zhura, Doctor of Medicine role: SUB_INVESTIGATOR lat: 53.9 lon: 27.56667 hasResults: False
nctId: NCT06365619 id: HCI168525 briefTitle: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma acronym: NeoRelapse overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-08 date: 2029-08 date: 2024-04-15 date: 2024-04-15 name: University of Utah class: OTHER briefSummary: The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy.
Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response. conditions: Melanoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Ipilimumab name: Nivolumab measure: Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery. measure: Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment. measure: Rate of adverse events that occur within 30 days post-surgery. measure: Rate of Event Free Survival (EFS). measure: Rate of Overall Survival (OS). measure: Objective response rate (ORR) defined as the proportion of subjects achieving a confirmed PR and CR as defined by RECIST 1.1 prior to surgical resection. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Huntsman Cancer Institute city: Salt Lake City state: Utah zip: 84112 country: United States lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06365606 id: CLS-015A briefTitle: Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis Syphilis Ab Test at the Point- Of-Care Sites overallStatus: RECRUITING date: 2024-03-14 date: 2024-04-10 date: 2024-05-29 date: 2024-04-15 date: 2024-04-15 name: bioLytical Laboratories class: INDUSTRY briefSummary: This study is a prospective cross-sectional study in which surgically non-invasive sample- taking is done only for the purpose of the study. Capillary (fingerstick) whole blood and plasma (i.e., obtained through venous EDTA whole blood collection and processing) are collected by a healthcare professional. The collected samples are tested in a routine testing environment, i.e., healthcare providers at conditions: Syphilis Infection conditions: Syphilis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: DOUBLE maskingDescription: Participants and the healthcare providers are not aware of the syphilis status. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 4500 type: ESTIMATED name: iStatis Syphilis Ab Test measure: Sensitivity and specificity of the iStatis Syphilis Ab Test sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Epicentre Health Research status: RECRUITING city: Hillcrest state: KwaZulu Natal zip: 3650 country: South Africa name: Cherie Cawood role: CONTACT phone: +27 828202955 email: cheriec@epicentre.org.za hasResults: False